504 results on '"McHutchison J"'
Search Results
2. Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
3. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis
4. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy
5. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection
6. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers
7. Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)
8. Ledipasvir/Sofosbuvir single tablet regimen is highly effective treatment for patients with HCV genotype 2 infection: O-25
9. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis
10. Supplement to: Telaprevir for previously untreated chronic hepatitis C virus infection.
11. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation
12. Sofosbuvir in combination with PEG IFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study
13. Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety
14. Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors
15. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase 3 studies
16. Supplement to: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
17. Supplement to: Ethical and scientific implications of the globalization of clinical research.
18. Ledipasvir + GS-9451 + peginterferon and ribavrin (PR) for six or 12 weeks achieves a high SVR12 in treatment naïve genotype 1 IL28B CC patients
19. Sofosbuvir and ribavirin achieves high SVR in patients with genotype 2 or 3 HCV infection who are without treatment options
20. Sofosbuvir in treatment-naïve patients with hepatitis C infection
21. Six years of tenofovir DF for chronic hepatitis B is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance
22. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection
23. Genomics in Pathogenesis of Cirrhosis
24. Genomics and the Management of Hepatitis
25. Cirrhosis in the Era of Genomic Medicine
26. Diagnosis, Management and Disease Mechanisms of Hepatitis in the Era of Genomic Medicine
27. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
28. Recipient IL28B Polymorphism Is an Important Independent Predictor of Posttransplant Diabetes Mellitus in Liver Transplant Patients with Chronic Hepatitis C
29. Increased lysyl oxidase gene expression is associated with advanced liver fibrosis
30. Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys
31. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C
32. Genetic Variation in IL28B: Impact on Drug Development for Chronic Hepatitis C Infection
33. IL28B polymorphism, jaundice during acute HCV infection, and spontaneous clearance in the german anti-D cohort
34. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response
35. IL28B polymorphism is associated with intrahepatic ISG expression and peginterferon-α/ribavirin response rate in chronic HCV infection
36. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor – a randomized placebo-controlled study in patients with chronic hepatitis C
37. Antiviral resistance and specifically targeted therapy for HCV (STAT-C)
38. Review article: investigational agents for chronic hepatitis C
39. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C
40. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase
41. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C
42. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C
43. Pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
44. Sustained virologic response with albinterferon alfa-2b plus ribavirin treatment in IFN-naïve, chronic hepatitis C genotype 1 patients
45. Interim (week 12) phase 2b virological efficacy and safety results of Albumin Interferon alpha 2b combined with ribavirin in genotype 1 chronic hepatitis C infection: the Australian cohort: 130
46. Favorable quality of life (QOL) in the first 12 weeks of treatment with albumin interferon alfa-2b compared with PEG-IFN in a Phase 2b study conducted in a genotype 1, IFN-naïve, chronic hepatitis C subjects: 121
47. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy
48. Insulin resistance and steatosis in hepatitis C virus infection
49. Antiviral treatment initiation costs in chronic hepatitis C
50. Effect of antiviral therapy on intermediate hepatobiliary (progenitor) cells during treatment of chronic hepatitis C: implications for hepatocarcinogenesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.